（来源：河北新闻网） 转自：河北新闻网 位于石家庄市国际生物医药园的绿叶嘉奥制药石家庄有限公司，工作人员正在进行设备的调试。 塔吊挥动长臂，厂房拔节生长，运输车辆往来穿梭，实验室里灯火通明……位于石家庄高新区的石家庄市国际生物医药园里，扑面而来的是项 目建设的火热气息与产业集聚的蓬勃活力。 创新沃土蓄发展势能，项目建设现场酣畅淋漓。目前，生物医药园汇聚了300余家企业，初步形成龙头企业引领、中型企业支撑、小微企业蓬 勃发展的良好生态。进入四季度以来，园区正以"冲刺"之姿，全力打好年度收官战，推动更多实验室技术走向生产线，为高质量发展持续注入 新动能。 优质项目串珠成链 绿叶嘉奥是高新区引进生物医药园的一家创新药研发企业，通过"资本运作、基金支持、以投代补"的方式，他们与政府合作共建项目。结合项 目引进和落地建设实际，高新区建立协同高效的项目入区评审和开展项目包联服务，绘制了招商引资项目入区落地流程图，以专家论证会、项 目小组会等形式，严把项目入区关，提高了生物医药园入园项目的质量。 发展活力，来源于一个个项目的扎实推进。 今年以来，高新区共引进生物医药类项目59个，依托生物医药园打造的良好发展环境，让更多企业 ...

Core Insights - The article highlights the rapid development of the biomedical industry in the Guangming District of Shenzhen, which is positioned as a key area for the construction of a comprehensive national scientific center [1][2] Group 1: Event Overview - The "Bay Area Pharmaceutical Research and Innovation in Guangming" salon was successfully held on December 12, 2025, organized by Shenzhen Weiguang Life Science Technology Holdings Group and supported by Shenzhen Securities Times [1] - The event gathered industry leaders, experts, and representatives from investment institutions to discuss the latest trends and future directions in the biomedical sector [1][2] Group 2: Industry Development - Guangming District has established a unique advantage system in innovative drug research and technology transfer, characterized by a cluster of large scientific devices, top research institutions, and a full-chain transformation ecosystem [2] - The district is home to over 23 major scientific innovation carriers, including 8 large scientific devices and 11 frontier interdisciplinary research platforms, with more than 20 facilities currently under construction or in operation [2] Group 3: Talent Pool - Guangming District has attracted a significant talent pool, including 59 academicians and over 5,000 PhD talents, contributing to a robust workforce of nearly 190,000 individuals in various fields [2][3] Group 4: Ecosystem and Collaboration - The Tianan Cloud Valley area integrates resources from medicine, education, research, and industry, forming a complete industrial ecosystem that supports the biomedical sector [3] - The salon aimed to create a dialogue platform among government, industry, academia, research, and investment to promote high-quality development in the biomedical industry [2][4] Group 5: Technological Innovations and Policy Support - Recent technological advancements, such as AI-assisted drug development and cell gene therapy, are reshaping the global biomedical industry [4] - Supportive national policies, including a reduction in clinical trial review times to 30 working days, are facilitating industry growth [4] Group 6: Future Opportunities - The salon featured discussions on the restructuring of the biomedical industry chain value and the challenges and opportunities that lie ahead [5] - Notable companies showcased their latest achievements in innovative drugs and differentiated dual-antibody drugs, fostering deeper integration between industry and academia [5]

Core Viewpoint - Shanghai is focusing on building a world-class modern socialist metropolis, with biomedicine as one of its key industries, leveraging its significant innovation resources [1] Group 1: Government Initiatives - Shanghai aims to enhance its technological innovation capabilities in the biomedicine sector and promote international development of the industry [1] - The city is committed to creating a globally influential biomedicine innovation hub [1] Group 2: Company Engagement - Boston Scientific is encouraged to optimize its operational layout in Shanghai and actively participate in the city's biomedicine industry development [1] - The company is invited to continue its participation in the China International Import Expo [1] Group 3: Business Environment - Shanghai will maintain a market-oriented, law-based, and international business environment to provide better conditions for various business entities [1]

Core Insights - The Xiong'an New Area held a successful conference focused on the high-quality development of the biopharmaceutical industry, emphasizing collaboration to enhance innovation and industry strength [1] - A strategic cooperation initiative for the biopharmaceutical industry was announced, aiming to build a comprehensive platform for scientific research and talent development [1] - The Hebei provincial government expressed strong support for the development of the biopharmaceutical sector in Xiong'an, aiming to create a demonstration effect [1] Industry Development - The biopharmaceutical industry is identified as one of the key sectors for development in Xiong'an New Area [1] - Future efforts will focus on optimizing the innovation ecosystem, strengthening resource support, and accelerating the transformation of policy benefits into tangible development outcomes [1] - The goal is to establish Xiong'an as an internationally leading innovation hub for the biopharmaceutical industry [1]

Core Insights - Shanghai is establishing itself as a global hub for biopharmaceutical innovation, with significant contributions in innovative drug and medical device development, accounting for 35% of the country's overseas licensing of innovative drugs [1][3] - The 2025 Shanghai International Biopharmaceutical Industry Week serves as a high-level platform for showcasing cutting-edge medical technologies and innovations, while also providing insights into the dynamics of Shanghai's biopharmaceutical industry [1][3] Industry Development - During the 14th Five-Year Plan period, Shanghai's biopharmaceutical sector has seen six research projects featured on the covers of top global academic journals, with a notable increase in research output in leading medical journals from 24 articles in 2021 to 52 articles in 2024, totaling 127 articles [3] - Shanghai aims to become a friendly city for global innovative drug and medical device development, with the establishment of a research and evaluation base for technical trade measures in the biopharmaceutical sector, which will help navigate international compliance challenges [3][4] Policy Support - In response to the growing demand for international expansion, Shanghai's government introduced policies in July 2024 to support the entire innovation chain of the biopharmaceutical industry, particularly focusing on facilitating the overseas licensing of innovative drugs [4] - Companies like Fuhong Hanlin have benefited from these policies, achieving EU market approval for their products and establishing a comprehensive system for clinical development and regulatory communication [4] Globalization Strategy - Local companies are increasingly viewing Shanghai as a strategic hub for research, production, and investment, while multinational corporations are deepening their involvement in the global innovation network [5] - The implementation of the drug marketing authorization holder system in Shanghai has encouraged global companies like Flextronics to establish production lines in the region, enhancing local manufacturing capabilities [5] High-End Medical Device Sector - Shanghai has launched an action plan to promote the development of the high-end medical device industry, with the establishment of three industrial clusters in Pudong, Minhang, and Jiading districts [6] - The focus is on reducing innovation costs and streamlining the innovation chain, creating a robust ecosystem that supports the transition from laboratory research to global market entry [6]

Core Insights - Shanghai's biopharmaceutical industry is experiencing rapid growth, with 38 license-out transactions expected to reach $30.7 billion in 2024, accounting for nearly one-third of the national total [1] - The industry has a compound annual growth rate of 8.94%, with a projected market size exceeding 1 trillion yuan this year [1] - Shanghai is building a world-class innovation ecosystem to enhance its role as a leading biopharmaceutical hub [1] Industry Development - Since 1993, biopharmaceuticals have been a key focus in Shanghai, with industrial output surpassing 200 billion yuan by 2024 [2] - Recent regulations and action plans have been implemented to support innovation across the entire biopharmaceutical value chain [2] - The establishment of the Shanghai Clinical Innovation Transformation Research Institute aims to facilitate the commercialization of clinical results from hospitals [2][3] Clinical Innovation - The clinical results commercialization model allows hospitals to transfer patent rights to the institute, which then partners with investors to form companies [3] - This model addresses challenges hospitals face in managing clinical results and enhances the efficiency of technology transfer [3] Foreign Investment and Local Innovation - Shanghai has attracted major international pharmaceutical companies, with 19 out of the top 20 global firms establishing headquarters or R&D centers in the city [5] - The city is fostering collaboration between multinational and local companies, enhancing innovation capabilities [5][6] Policy Support - Shanghai has introduced comprehensive policies covering the entire biopharmaceutical industry chain, promoting R&D and manufacturing [8] - The city has recognized significant achievements in biopharmaceutical innovation, such as the development of the first domestically produced targeted drug for colorectal cancer [8][9] Financial Investment - The biopharmaceutical sector relies heavily on patient capital due to its high-risk and long-cycle nature [12] - Shanghai has established a 22.5 billion yuan biopharmaceutical industry fund to support strategic mergers and acquisitions [13][14] - From 2021 to 2024, the sector has seen cumulative financing of 238.37 billion yuan, with 1,494 financing events [13]

Group 1 - The core viewpoint emphasizes Shanghai's commitment to developing the biopharmaceutical industry as one of its three key leading industries, highlighting its innovation resources and industry scale [1] - Shanghai aims to enhance its technological innovation capabilities in the biopharmaceutical sector and promote international development, inviting global companies like Novo Nordisk to participate and integrate into local R&D and supply chains [1] - Novo Nordisk expresses confidence in Shanghai's vision to become a global leader in life sciences and healthcare, committing to deepen cooperation with local government and academic institutions to address chronic disease prevention and treatment [1] Group 2 - Novo Nordisk is a globally recognized biopharmaceutical company, ranked 368th in the Fortune Global 500, with established regional headquarters and open innovation centers in Shanghai [2]

Core Viewpoint - Shanghai has introduced measures to promote the high-quality development of commercial health insurance, aiming to enhance insurance services for public health and support the innovation of the biopharmaceutical industry [1] Group 1: Policy Measures - The measures consist of 5 areas and 18 specific actions designed to improve the accessibility and affordability of innovative drugs and medical devices [1] - There is an emphasis on deepening the payment mechanism for innovative drugs and medical devices, facilitating their entry into hospitals, directories, and prescriptions [1] - Innovative drug applications within the scope of commercial health insurance will not be included in the disease-based payment range, encouraging insurance companies to use clinical trial data for pricing [1] Group 2: Integration of Insurance Systems - Shanghai plans to enhance the functionality of the "Shanghai Insurance Code" to optimize the synchronous settlement model between medical insurance and commercial insurance [1] - Improvements will be made to direct compensation service processes, creating a proactive compensation system that integrates medical, health insurance, and commercial insurance data [1] - The goal is to achieve a unified compensation system, referred to as "one code for compensation" [1] Group 3: Impact on Public Health - The introduction of these measures is expected to position commercial health insurance as a crucial pillar in the public health security system [1] - The measures aim to provide the public with more comprehensive, diverse, and convenient health protection [1]

Group 1 - In the first seven months of this year, Jiangsu approved 14 innovative drugs for market, surpassing the total of 13 from the previous year, accounting for nearly 30% of the 49 innovative drugs approved nationwide [1] - The approved innovative drugs target diseases such as tumors, spondyloarthritis, and influenza, with notable products including Suweisituzumab, the first anti-angiogenesis drug for "platinum-resistant" ovarian cancer in China [1] - Heng Rui Medicine has increased its innovation efforts, with R&D investment accounting for 29.4% of sales revenue last year, totaling 46 billion yuan, and over 90 self-innovative products currently in clinical development [1] Group 2 - Jiangsu is promoting industrial R&D innovation while optimizing drug review and approval processes, exemplified by the approval of the first segmented production model antibody-drug conjugate in the country [2] - The segmented production model allows for specialized production management and quality control at different sites, enhancing resource allocation and collaboration within the industry [2] - Jiangsu has established seven national key laboratories in the biopharmaceutical field and has been approved to build the first national technology innovation center in this area, leading to a robust innovation ecosystem [2]

Group 1 - The core viewpoint of the article is the issuance of measures to promote the high-quality development of commercial health insurance to support innovation in the biopharmaceutical industry [1] Group 2 - The measures aim to broaden the service population of commercial health insurance, focusing on the needs of the elderly, children, and patients with chronic diseases [1] - Insurance institutions are encouraged to include elderly individuals and those with pre-existing conditions in their coverage, based on controllable risks and commercial sustainability [1] - The use of big data and industry experience data is recommended to reasonably determine insurance product rates and to relax underwriting conditions [1] - There is an emphasis on providing diversified customized services and increasing health coverage for specific groups such as new citizens and those in emerging industries and business formats [1]